• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Oncorus Inc.

    7/19/23 4:30:48 PM ET
    $ONCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ONCR alert in real time by email
    S-8 POS 1 s-8_pos_filing_270839_-_.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on July 19, 2023

     

    Registration No. 333-249425

    Registration No. 333-254097

    Registration No. 333-263393

    Registration No. 333-270839

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    Post-Effective Amendment No. 1

    to

    Form S-8 Registration Statement No. 333-249425

    Form S-8 Registration Statement No. 333-254097

    Form S-8 Registration Statement No. 333-263393

    Form S-8 Registration Statement No. 333-270839

     

    UNDER

    THE SECURITIES ACT OF 1933

    Oncorus, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

    47-3779757

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

     

     

    4 Corporate Drive

    Andover, Massachusetts

    01810

    (Address of principal executive offices)

    (Zip Code)

     

    Oncorus, Inc. 2016 Equity Incentive Plan, as amended

    Oncorus, Inc. 2020 Equity Incentive Plan

    Oncorus, Inc. 2020 Employee Stock Purchase Plan

    (Full titles of the plans)

    Brian J. Shea

    President and Interim Chief Executive Officer

    General Counsel & Secretary

    Oncorus, Inc.

    4 Corporate Drive

    Andover, Massachusetts 01810

    (339) 240-3330

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    With copies to:

    Marc A. Recht

    Brian F. Leaf

    Courtney T. Thorne

    Cooley LLP

    500 Boylston Street

    Boston, Massachusetts 02116

    (617) 937-2300


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

     

     

     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (each, a "Registration Statement" and, collectively, the "Registration Statements"), previously filed by Oncorus, Inc. (the "Company"), with the U.S. Securities and Exchange Commission (the “SEC”):

    •
    Registration Statement on Form S-8 (File No. 333-249425), originally filed with the SEC on October 9, 2020, pertaining to the registration of 2,819,048 shares of the Company’s common stock, $0.0001 par value per share ("Common Stock"), under the Company’s 2020 Equity Incentive Plan (the "2020 Plan"), 280,000 shares of Common Stock under the Company’s 2020 Employee Share Purchase Plan (the "2020 ESPP"), and 2,109,151 shares of Common Stock under the Company's 2016 Equity Incentive Plan, as amended (the "2016 Plan");
    •
    Registration Statement on Form S-8 (File No. 333-254097), originally filed with the SEC on March 10, 2021, pertaining to the registration of an additional 1,130,896 shares of Common Stock under the 2020 Plan;
    •
    Registration Statement on Form S-8 (File No. 333-263393), originally filed with the SEC on March 9, 2022, pertaining to the registration of an additional 1,292,458 shares of Common Stock under the 2020 Plan; and
    •
    Registration Statement on Form S-8 (File No. 333-270839), originally filed with the SEC on March 24, 2023, pertaining to the registration of an additional 1,298,656 shares of Common Stock under the 2020 Plan and an additional 259,731 shares of Common Stock under the 2020 ESPP.

    The Company is filing this Post-Effective Amendment No. 1 to the Registration Statements 333-249425; 333-254097; 333-263393; and 333-270839 to withdraw and remove from registration any and all shares of Common Stock that remain unsold or otherwise unissued under the Registration Statements.

    On June 6, 2023, the Company’s board of directors approved a Plan of Dissolution (the "Plan of Dissolution") which, following the approval by the Company’s stockholders at the special meeting to be held on July 28, 2023, authorizes the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution.

    In connection with the Plan of Dissolution, the Company has terminated any and all offerings of its securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by the Company in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes and withdraws from registration all securities of the Company registered pursuant to the Registration Statements that remain unsold as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Company hereby terminates the effectiveness of the Registration Statements.

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in Andover, Massachusetts on July 19, 2023.

     

     

     

     

    ONCORUS, INC.

     

     

     

     

    Date: July 19, 2023

     

     

     

    By:

     

    /s/ Brian J. Shea

     

     

     

     

    Name:

     

    Brian J. Shea

     

     

     

     

    Title:

     

    President and Interim Chief Executive Officer

     

     

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

     

    Name

    Position

    Date

    /s/ Brian J. Shea

    President and Interim Chief Executive Officer

    July 19, 2023

    Brian J. Shea

    (Principal Executive Officer)

    /s/ Alexander Nolte

    Interim Chief Financial Officer

    July 19, 2023

    Alexander Nolte

    (Principal Financial Officer and Principal Accounting Officer)

    /s/ Ted Ashburn

    Chairman of the Board of Directors

    July 19, 2023

    Theodore (Ted) Ashburn, M.D., Ph.D.

    *

    Director

    July 19, 2023

    Mitchell Finer, Ph.D.

    *

    Director

    July 19, 2023

    Douglas M. Fambrough, III, Ph.D.

    *

    Director

    July 19, 2023

    Mary Kay Fenton

    *

    Director

    July 19, 2023

    Spencer Nam

    *

    Director

    July 19, 2023

    Eric Rubin

    *

    Director

    July 19, 2023

    Barbara Yanni

     

     

     

     

     

     

     

     

     

     

    *By:

    /s/ Ted Ashburn

     

     

     

    Theodore (Ted) Ashburn, M.D., Ph.D.

     

     

     

    Attorney-in-fact

     

     

     

     

     


    Get the next $ONCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONCR

    DatePrice TargetRatingAnalyst
    More analyst ratings